Innovating Works

BIOKERALTY

Desconocido
TUAI: Towards an Understanding of Artificial Intelligence via a transparent open and explainable perspect... BIOKERALTY RESEARCH INSTITUTE AIE participó en un HORIZON EUROPE: HORIZON-MSCA-2023-DN-01 The focus of the TUAI project will be on the highest quality doctoral training on sustainable the AI that is used in smart manufacturing, sm...
2024-06-28 - 2028-09-30 | Financiado
IDEAL PhD: IMDEA Nanociencia Doctoral Training Programme in Nanoscience BIOKERALTY RESEARCH INSTITUTE AIE participó en un HORIZON EUROPE: HORIZON-MSCA-2021-COFUND-01 IDEAL PhD programme is a new doctoral fellowship programme promoted by Fundación IMDEA Nanociencia (IMDEA Nano) that aims to attract 12 tale...
2022-09-22 - 2028-09-30 | Financiado
INNO4COV-19: Boosting Innovation for COVID 19 Diagnostic Prevention and Surveillance. BIOKERALTY RESEARCH INSTITUTE AIE participó en un H2020: H2020-SC1-PHE-CORONAVIRUS-2020-2 The novel corona virus causing COVID-19 overwhelmed Europe and the world in just a few weeks’ time. Small and Medium-sized Entrerprises (SME...
2020-10-13 - 2022-11-30 | Financiado
SAFE-N-MEDTECH: SAFETY TESTING IN THE LIFE CYCLE OF NANOTECHNOLOGY ENABLED MEDICAL TECHNOLOGIES FOR HEALTH. Society and clinical practice pose a growing demand on novel biomaterials, ICT, micro and nanotechnologies for innovative medical devices an...
2019-03-05 - 2023-09-30 | Financiado
REFINE: Regulatory Science Framework for Nano bio material based Medical Products and Devices BIOKERALTY RESEARCH INSTITUTE AIE participó en un H2020: H2020-NMBP-2016-2017 REFINE proposes a Regulatory Science Framework for the risk-benefit assessment of medical products and medical devices that are based on nan...
2017-11-29 - 2022-02-28 | Financiado
CLINGLIO: A Clinical Phase IIB trial with 2OHOA in patients with newly diagnosed malignant glioma. BIOKERALTY RESEARCH INSTITUTE AIE participó en un H2020: H2020-SC1-2016-2017 "Glioma is a rare brain cancer with one of the highest mortality rates. It is considered an orphan disease due to its low prevalence (less t...
2017-11-27 - 2022-05-31 | Financiado
Smart-4-Fabry: Smart multifunctional GLA nanoformulation for Fabry disease BIOKERALTY RESEARCH INSTITUTE AIE participó en un H2020: H2020-NMBP-2016-2017 Lysosomal storage disorders (LSD) diseases are a group of rare diseases that currently lack a definitive cure. LSD incidence is about 1:5,00...
2016-11-22 - 2020-12-31 | Financiado
NoCanTher: Nanomedicine upscaling for early clinical phases of multimodal cancer therapy BIOKERALTY RESEARCH INSTITUTE AIE participó en un H2020: H2020-NMP-2014-2015 This project has been amended in July 2019 to better align the described tasks and timeline with the current status of the project. The pre...
2016-03-08 - 2021-09-30 | Financiado
TAT-CF: Novel therapeutic approaches for the treatment of cystic fibrosis based on small molecule transmembr... BIOKERALTY RESEARCH INSTITUTE AIE participó en un H2020: H2020-PHC-2014-2015 This project will develop an innovative therapeutic approach for the treatment of Cystic Fibrosis (CF). This condition originates from the d...
2015-12-01 - 2018-12-31 | Financiado
BERENICE: Benznidazol and Triazol REsearch group for Nanomedicine and Innovation on Chagas diseasE BIOKERALTY RESEARCH INSTITUTE AIE participó en un FP7: The BERENICE consortium is aiming at providing a new and cost-effective solution to a better treatment for Chagas chronic patients. Please s...
Financiado
THERAGLIO: Microbubble driven multimodal imaging and theranostics for gliomas BIOKERALTY RESEARCH INSTITUTE AIE participó en un FP7: Microbubbles (MBs) are used as contrast agent in ultrasound (US) imaging for a variety of tumours while little has been done for glioblastom...
Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.